Humana Inc. $HUM Shares Sold by Cetera Investment Advisers

Key Points

• Cetera Investment Advisers cut its Humana stake by 47.8% in the first quarter, selling 6,128 shares and retaining 6,687 shares valued at approximately $1.16 million.
• Other major institutions, including Capital International Investors and Pzena Investment Management, increased their positions; institutional investors collectively own 92.38% of Humana’s stock.
• Humana’s latest quarterly results exceeded expectations, with EPS of $7.61 and revenue of $40.89 billion, while analyst opinions remain mixed and the consensus rating is Hold with a $395.22 price target.

Cetera Investment Advisers reduced its stake in Humana Inc. (NYSE:HUM - Free Report) by 47.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,687 shares of the insurance provider's stock after selling 6,128 shares during the quarter. Cetera Investment Advisers' holdings in Humana were worth $1,160,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of HUM. Vanguard Group Inc. lifted its holdings in shares of Humana by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider's stock worth $3,652,890,000 after purchasing an additional 106,030 shares during the period. Capital International Investors increased its stake in Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock valued at $1,490,239,000 after buying an additional 3,097,571 shares during the period. Pzena Investment Management LLC raised its position in Humana by 34.3% during the 1st quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider's stock worth $948,614,000 after buying an additional 1,398,774 shares during the last quarter. State Street Corp raised its position in Humana by 1.8% during the 4th quarter. State Street Corp now owns 5,462,549 shares of the insurance provider's stock worth $1,403,877,000 after buying an additional 97,211 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Humana by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 3,184,569 shares of the insurance provider's stock worth $812,540,000 after acquiring an additional 23,732 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Higher earnings outlook: Zacks Research raised its Q1 2027 EPS estimate to $9.04 from $8.70, suggesting improved expectations for Humana’s near-term profitability. The firm nonetheless maintained a Hold rating. Humana earnings estimate article
• Positive Sentiment: Medicaid and underserved-member expansion: Humana is partnering with Cityblock Health to support low-income and dual-eligible Medicare Advantage members. The move could strengthen care coordination and support growth in Medicaid and Medicare-related services. Humana Cityblock partnership article
• Positive Sentiment: Caregiver-retention initiative: A HealthStream agreement will fund 1,000 caregiver scholarships and provide recruitment and retention tools in Indiana, potentially supporting staffing at Humana’s CenterWell operations. Humana HealthStream deal article
• Positive Sentiment: Brokerage price-target support: JPMorgan raised its price target for HUM to $393, indicating modest upside relative to the referenced trading level. JPMorgan Humana price target article
• Neutral Sentiment: Leadership change: Humana appointed James Holland as president of its Medicaid business, underscoring the company’s focus on Medicaid but creating an execution milestone for investors. Humana Medicaid leadership article
• Neutral Sentiment: Legal proceeding: Humana agreed not to reference Teva’s Israeli identity during an upcoming U.S. drug-price-fixing trial. The agreement is procedural and does not indicate a new financial liability for Humana. Humana Teva trial article
• Negative Sentiment: Medicare Advantage membership reduction: Humana reportedly plans to drop approximately 600,000 Medicare Advantage members in 2027. Although the move may improve plan economics, investors may view the lost membership and related revenue as a near-term headwind. Humana Medicare Advantage membership article
• Negative Sentiment: More cautious rating: Zacks Research downgraded Humana from Strong Buy to Hold, limiting the positive impact from the firm’s higher EPS forecast. Zacks Humana rating

Humana Trading Down 1.1%

Shares of HUM stock opened at $384.50 on Friday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $46.17 billion, a price-to-earnings ratio of 36.38, a price-to-earnings-growth ratio of 2.22 and a beta of 0.72. The firm's 50 day moving average price is $381.25 and its two-hundred day moving average price is $274.88. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. During the same period in the prior year, the company earned $6.27 EPS. The firm's revenue was up 26.2% on a year-over-year basis. On average, analysts anticipate that Humana Inc. will post 9.09 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on HUM shares. Barclays lifted their target price on shares of Humana from $344.00 to $407.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Leerink Partners upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $513.00 price objective for the company in a research report on Thursday, July 30th. Wells Fargo & Company raised Humana from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $227.00 to $502.00 in a report on Monday, July 13th. Bank of America raised shares of Humana from a "neutral" rating to a "buy" rating and set a $500.00 price objective on the stock in a research note on Wednesday, July 29th. Finally, Raymond James Financial lowered Humana from an "outperform" rating to a "market perform" rating in a research note on Thursday, July 30th. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $395.22.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source